Home >  Gastroenterology MDTV >  Gastroenterology Shorts MDTV >  New Drug Delivery Method...

New Drug Delivery Method Targets Gut, Reduces IBD Medication Doses by Up to 10 Times- Study

By - Dr. Garima Soni
Published On 2025-05-03 02:30 GMT   |   Update On 2025-05-03 02:30 GMT
Advertisement
A new drug delivery technique, GlycoCaging, could transform the treatment of inflammatory bowel disease (IBD), allowing medication to be delivered directly to the gut at much lower doses. The proof-of-concept study, published in Science, demonstrates that this method can effectively target the lower gut in mice, using up to 10 times less medication than current therapies.
GlycoCaging works by chemically bonding a drug, such as a
Advertisement
steroid, to a molecule found in fruits and vegetables. This molecule can only be broken down by specific bacteria in the gut. Once the drug reaches the lower intestine, the bacteria break the bond, releasing the medication where it's needed.
"With this technique, we have the ability to deliver not just steroids, but a range of drugs including antimicrobial compounds directly to the gut, potentially helping people with inflammatory bowel disease, gut infections and more," said Dr. Harry Brumer, co-senior author and professor in UBC’s department of chemistry.
In trials involving mice with IBD, GlycoCaged steroids were equally effective as high-dose treatments but resulted in much lower drug levels in the rest of the body, reducing potential side effects.
The team found the necessary bacteria in fecal samples from 33 individuals, both with and without IBD, indicating that the system may work in humans. With a patent secured, the researchers are now seeking funding for advanced preclinical and human clinical trials.
Reference: Ma, W. J., et al. (2025). Bespoke plant glycoconjugates for gut microbiota-mediated drug targeting. Science. doi.org/10.1126/science.adk7633.
Full View
Tags:    
Article Source : Science

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Garima Soni

Dr. Garima Soni holds a BDS (Bachelor of Dental Surgery) from Government Dental College, Raipur, Chhattisgarh, and an MDS (Master of Dental Surgery) specializing in Orthodontics and Dentofacial Orthopedics from Maitri College of Dentistry and Research Centre. At medical dialogues she focuses on dental news and dental and medical fact checks against medical/dental mis/disinformation

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Caltech Engineers Develop Smart Ingestible Capsule for Real-Time Gut Health Monitoring

New Blood Test May Detect Early Liver Transplant Rejection: Study Suggests

Six in Ten with Type 2 Diabetes Have Fatty Liver: Study Finds

Why Alcohol-Related Liver Disease Are Rising in Women? Study Sheds Light

Clinical Trial Shows Diabetes Drug May Help Treat Liver Inflammation

How Plastic Particles in Food Affect Liver Function: Study Sheds Light

Mediterranean Diet Shows Potential for Easing Irritable Bowel Syndrome: Study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan